Caris Life Sciences, Inc. (NASDAQ: CAI) Stock Competitors & Peer Comparison
See CAI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CAI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CAI | $25.23 | -3.07% | 7.1B | 70.92 | $0.36 | N/A |
| VRTX | $547.09 | +0.85% | 138.6B | 28.74 | $19.03 | N/A |
| MRNA | $254.19 | +5.27% | 101.5B | -31.20 | -$8.15 | N/A |
| REGN | $904.35 | +0.16% | 93.6B | 19.82 | $45.63 | +0.41% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $927.21 | +3.63% | 55.3B | 33.44 | $27.73 | N/A |
| ONC | $406.96 | +5.09% | 43.5B | 71.66 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.90 | +16.47% | 41.4B | -1.12 | -$8.82 | N/A |
| RVMD | $192.28 | +8.24% | 41.2B | -21.79 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
CAI vs VRTX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, VRTX has a market cap of 138.6B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while VRTX trades at $547.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas VRTX's P/E ratio is 28.74. In terms of profitability, CAI's ROE is +0.16%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, CAI is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
CAI vs MRNA Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, MRNA has a market cap of 101.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while MRNA trades at $254.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas MRNA's P/E ratio is -31.20. In terms of profitability, CAI's ROE is +0.16%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, CAI is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for CAI.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
CAI vs REGN Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, REGN has a market cap of 93.6B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while REGN trades at $904.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas REGN's P/E ratio is 19.82. In terms of profitability, CAI's ROE is +0.16%, compared to REGN's ROE of +0.15%. Regarding short-term risk, CAI is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
CAI vs VRNA Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CAI's ROE is +0.16%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, CAI is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for CAI.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
CAI vs ARGX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ARGX trades at $927.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ARGX's P/E ratio is 33.44. In terms of profitability, CAI's ROE is +0.16%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, CAI is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
CAI vs ONC Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ONC has a market cap of 43.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ONC trades at $406.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ONC's P/E ratio is 71.66. In terms of profitability, CAI's ROE is +0.16%, compared to ONC's ROE of +0.18%. Regarding short-term risk, CAI is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
CAI vs SGEN Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CAI's ROE is +0.16%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CAI is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
CAI vs RVMDW Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, RVMDW has a market cap of 41.4B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while RVMDW trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas RVMDW's P/E ratio is -1.12. In terms of profitability, CAI's ROE is +0.16%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, CAI is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
CAI vs RVMD Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, RVMD has a market cap of 41.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while RVMD trades at $192.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas RVMD's P/E ratio is -21.79. In terms of profitability, CAI's ROE is +0.16%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, CAI is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RVMD's competition here
Genmab A/S (NASDAQ: GMAB)
CAI vs GMAB Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, GMAB has a market cap of 33B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while GMAB trades at $53.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas GMAB's P/E ratio is 40.41. In terms of profitability, CAI's ROE is +0.16%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, CAI is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for CAI.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
CAI vs ROIV Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ROIV has a market cap of 28.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ROIV trades at $38.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ROIV's P/E ratio is -37.00. In terms of profitability, CAI's ROE is +0.16%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, CAI is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
CAI vs INSM Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while INSM trades at $114.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas INSM's P/E ratio is -40.59. In terms of profitability, CAI's ROE is +0.16%, compared to INSM's ROE of -0.83%. Regarding short-term risk, CAI is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for CAI.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
CAI vs INCY Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while INCY trades at $119.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas INCY's P/E ratio is 16.08. In terms of profitability, CAI's ROE is +0.16%, compared to INCY's ROE of +0.07%. Regarding short-term risk, CAI is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for CAI.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
CAI vs UTHR Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, UTHR has a market cap of 24.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while UTHR trades at $562.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas UTHR's P/E ratio is 20.11. In terms of profitability, CAI's ROE is +0.16%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CAI is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for CAI.Check UTHR's competition here
BioNTech SE (NASDAQ: BNTX)
CAI vs BNTX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, BNTX has a market cap of 21.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while BNTX trades at $87.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas BNTX's P/E ratio is -11.35. In terms of profitability, CAI's ROE is +0.16%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, CAI is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check BNTX's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
CAI vs ALNY Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ALNY has a market cap of 20.9B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ALNY trades at $155.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ALNY's P/E ratio is 7.87. In terms of profitability, CAI's ROE is +0.16%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, CAI is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ALNY's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
CAI vs BGNE Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CAI's ROE is +0.16%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, CAI is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
CAI vs DNA-WT Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CAI's ROE is +0.16%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, CAI is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for CAI.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
CAI vs EXEL Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, EXEL has a market cap of 17.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while EXEL trades at $69.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas EXEL's P/E ratio is 19.87. In terms of profitability, CAI's ROE is +0.16%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, CAI is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for CAI.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
CAI vs ASND Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ASND has a market cap of 16.9B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ASND trades at $256.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ASND's P/E ratio is -106.12. In terms of profitability, CAI's ROE is +0.16%, compared to ASND's ROE of +1.90%. Regarding short-term risk, CAI is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
CAI vs NBIX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, NBIX has a market cap of 16.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while NBIX trades at $164.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas NBIX's P/E ratio is 23.79. In terms of profitability, CAI's ROE is +0.16%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, CAI is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
CAI vs JAZZ Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while JAZZ trades at $234.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas JAZZ's P/E ratio is 8.75. In terms of profitability, CAI's ROE is +0.16%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, CAI is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for CAI.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
CAI vs BBIO Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, BBIO has a market cap of 14.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while BBIO trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas BBIO's P/E ratio is -24.43. In terms of profitability, CAI's ROE is +0.16%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, CAI is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for CAI.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
CAI vs SMMT Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, SMMT has a market cap of 13B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while SMMT trades at $16.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas SMMT's P/E ratio is -14.58. In terms of profitability, CAI's ROE is +0.16%, compared to SMMT's ROE of -1.59%. Regarding short-term risk, CAI is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for CAI.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
CAI vs KRTX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CAI's ROE is +0.16%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CAI is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
CAI vs HALO Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, HALO has a market cap of 11.8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while HALO trades at $103.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas HALO's P/E ratio is 19.35. In terms of profitability, CAI's ROE is +0.16%, compared to HALO's ROE of +5.44%. Regarding short-term risk, CAI is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for CAI.Check HALO's competition here
Bio-Techne Corporation (NASDAQ: TECH)
CAI vs TECH Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while TECH trades at $72.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas TECH's P/E ratio is 37.52. In terms of profitability, CAI's ROE is +0.16%, compared to TECH's ROE of +0.09%. Regarding short-term risk, CAI is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for CAI.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
CAI vs RNAM Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CAI's ROE is +0.16%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, CAI is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RNAM's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
CAI vs KYMR Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, KYMR has a market cap of 11.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while KYMR trades at $131.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas KYMR's P/E ratio is -36.38. In terms of profitability, CAI's ROE is +0.16%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, CAI is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for CAI.Check KYMR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
CAI vs BMRN Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while BMRN trades at $56.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas BMRN's P/E ratio is 26.93. In terms of profitability, CAI's ROE is +0.16%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, CAI is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check BMRN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
CAI vs PCVX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while PCVX trades at $63.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas PCVX's P/E ratio is -8.37. In terms of profitability, CAI's ROE is +0.16%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, CAI is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
CAI vs SYRE Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, SYRE has a market cap of 9.6B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while SYRE trades at $103.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas SYRE's P/E ratio is -53.26. In terms of profitability, CAI's ROE is +0.16%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, CAI is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check SYRE's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
CAI vs RXDX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CAI's ROE is +0.16%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CAI is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RXDX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
CAI vs MDGL Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, MDGL has a market cap of 9.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while MDGL trades at $399.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas MDGL's P/E ratio is -31.27. In terms of profitability, CAI's ROE is +0.16%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, CAI is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for CAI.Check MDGL's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
CAI vs TGTX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, TGTX has a market cap of 9.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while TGTX trades at $59.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas TGTX's P/E ratio is 21.68. In terms of profitability, CAI's ROE is +0.16%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, CAI is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check TGTX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
CAI vs IBRX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, IBRX has a market cap of 9.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while IBRX trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas IBRX's P/E ratio is -8.90. In terms of profitability, CAI's ROE is +0.16%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, CAI is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check IBRX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
CAI vs NUVL Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas NUVL's P/E ratio is -21.79. In terms of profitability, CAI's ROE is +0.16%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CAI is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for CAI.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
CAI vs CRNX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas CRNX's P/E ratio is -16.86. In terms of profitability, CAI's ROE is +0.16%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CAI is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CRNX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
CAI vs KRYS Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while KRYS trades at $300.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas KRYS's P/E ratio is 37.68. In terms of profitability, CAI's ROE is +0.16%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, CAI is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for CAI.Check KRYS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
CAI vs IMGN Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CAI's ROE is +0.16%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CAI is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
CAI vs PTGX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while PTGX trades at $132.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas PTGX's P/E ratio is 128.05. In terms of profitability, CAI's ROE is +0.16%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, CAI is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
CAI vs APGE Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas APGE's P/E ratio is -31.19. In terms of profitability, CAI's ROE is +0.16%, compared to APGE's ROE of -0.30%. Regarding short-term risk, CAI is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
CAI vs BPMC Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CAI's ROE is +0.16%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, CAI is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for CAI.Check BPMC's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
CAI vs ARWR Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ARWR has a market cap of 8.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ARWR trades at $58.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ARWR's P/E ratio is -25.84. In terms of profitability, CAI's ROE is +0.16%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, CAI is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ARWR's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
CAI vs CERE Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas CERE's P/E ratio is -16.47. In terms of profitability, CAI's ROE is +0.16%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CAI is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CERE's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
CAI vs TWST Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, TWST has a market cap of 8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while TWST trades at $120.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas TWST's P/E ratio is -54.47. In terms of profitability, CAI's ROE is +0.16%, compared to TWST's ROE of -0.30%. Regarding short-term risk, CAI is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for CAI.Check TWST's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
CAI vs PRAX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, PRAX has a market cap of 7.8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while PRAX trades at $277.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas PRAX's P/E ratio is -21.49. In terms of profitability, CAI's ROE is +0.16%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, CAI is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check PRAX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
CAI vs RYTM Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, RYTM has a market cap of 7.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while RYTM trades at $112.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas RYTM's P/E ratio is -36.07. In terms of profitability, CAI's ROE is +0.16%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, CAI is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RYTM's competition here
Abivax S.A. (NASDAQ: ABVX)
CAI vs ABVX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ABVX trades at $85.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ABVX's P/E ratio is -14.06. In terms of profitability, CAI's ROE is +0.16%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, CAI is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ABVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
CAI vs CYTK Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, CYTK has a market cap of 7.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while CYTK trades at $53.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas CYTK's P/E ratio is -7.44. In terms of profitability, CAI's ROE is +0.16%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, CAI is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CYTK's competition here
Metsera, Inc. (NASDAQ: MTSR)
CAI vs MTSR Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CAI's ROE is +0.16%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, CAI is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for CAI.Check MTSR's competition here
10x Genomics, Inc. (NASDAQ: TXG)
CAI vs TXG Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, TXG has a market cap of 7.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while TXG trades at $59.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas TXG's P/E ratio is -100.53. In terms of profitability, CAI's ROE is +0.16%, compared to TXG's ROE of -0.08%. Regarding short-term risk, CAI is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for CAI.Check TXG's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
CAI vs AXSM Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, AXSM has a market cap of 7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while AXSM trades at $132.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas AXSM's P/E ratio is -34.56. In terms of profitability, CAI's ROE is +0.16%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, CAI is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for CAI.Check AXSM's competition here
Merus N.V. (NASDAQ: MRUS)
CAI vs MRUS Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CAI's ROE is +0.16%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, CAI is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for CAI.Check MRUS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
CAI vs ORKA Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ORKA has a market cap of 6.8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ORKA trades at $102.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ORKA's P/E ratio is -52.98. In terms of profitability, CAI's ROE is +0.16%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, CAI is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ORKA's competition here
CG Oncology Inc. (NASDAQ: CGON)
CAI vs CGON Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, CGON has a market cap of 6.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while CGON trades at $75.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas CGON's P/E ratio is -28.25. In terms of profitability, CAI's ROE is +0.16%, compared to CGON's ROE of -0.19%. Regarding short-term risk, CAI is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for CAI.Check CGON's competition here
Arcellx, Inc. (NASDAQ: ACLX)
CAI vs ACLX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CAI's ROE is +0.16%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, CAI is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
CAI vs RETA Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas RETA's P/E ratio is -66.29. In terms of profitability, CAI's ROE is +0.16%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CAI is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RETA's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
CAI vs IONS Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, IONS has a market cap of 6.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while IONS trades at $39.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas IONS's P/E ratio is -12.05. In terms of profitability, CAI's ROE is +0.16%, compared to IONS's ROE of -1.11%. Regarding short-term risk, CAI is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for CAI.Check IONS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
CAI vs IMVT Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, IMVT has a market cap of 6.3B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while IMVT trades at $30.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas IMVT's P/E ratio is -10.82. In terms of profitability, CAI's ROE is +0.16%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, CAI is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for CAI.Check IMVT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
CAI vs CNTA Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas CNTA's P/E ratio is -22.63. In terms of profitability, CAI's ROE is +0.16%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CAI is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CNTA's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
CAI vs KOD Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, KOD has a market cap of 6.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while KOD trades at $99.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas KOD's P/E ratio is -23.82. In terms of profitability, CAI's ROE is +0.16%, compared to KOD's ROE of -2.73%. Regarding short-term risk, CAI is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for CAI.Check KOD's competition here
Belite Bio, Inc (NASDAQ: BLTE)
CAI vs BLTE Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while BLTE trades at $154.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas BLTE's P/E ratio is -82.52. In terms of profitability, CAI's ROE is +0.16%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, CAI is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for CAI.Check BLTE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
CAI vs LGND Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while LGND trades at $306.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas LGND's P/E ratio is 33.58. In terms of profitability, CAI's ROE is +0.16%, compared to LGND's ROE of +0.05%. Regarding short-term risk, CAI is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for CAI.Check LGND's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
CAI vs TERN Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas TERN's P/E ratio is -51.41. In terms of profitability, CAI's ROE is +0.16%, compared to TERN's ROE of -0.14%. Regarding short-term risk, CAI is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check TERN's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
CAI vs MIRM Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while MIRM trades at $93.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas MIRM's P/E ratio is -6.44. In terms of profitability, CAI's ROE is +0.16%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, CAI is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for CAI.Check MIRM's competition here
Veradermics, Incorporated (NYSE: MANE)
CAI vs MANE Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, MANE has a market cap of 5.8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while MANE trades at $138.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas MANE's P/E ratio is -44.17. In terms of profitability, CAI's ROE is +0.16%, compared to MANE's ROE of -0.38%. Regarding short-term risk, CAI is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check MANE's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CAI vs SRRK Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while SRRK trades at $46.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas SRRK's P/E ratio is -13.60. In terms of profitability, CAI's ROE is +0.16%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, CAI is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for CAI.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
CAI vs CDTX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CAI's ROE is +0.16%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, CAI is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
CAI vs ABCM Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CAI's ROE is +0.16%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CAI is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
CAI vs ISEE Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CAI's ROE is +0.16%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CAI is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ISEE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
CAI vs COGT Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while COGT trades at $31.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas COGT's P/E ratio is -15.00. In terms of profitability, CAI's ROE is +0.16%, compared to COGT's ROE of -0.71%. Regarding short-term risk, CAI is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for CAI.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
CAI vs PTCT Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while PTCT trades at $65.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas PTCT's P/E ratio is -46.74. In terms of profitability, CAI's ROE is +0.16%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, CAI is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for CAI.Check PTCT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
CAI vs APLS Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas APLS's P/E ratio is 38.35. In terms of profitability, CAI's ROE is +0.16%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CAI is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for CAI.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
CAI vs ERAS Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ERAS trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ERAS's P/E ratio is -15.49. In terms of profitability, CAI's ROE is +0.16%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, CAI is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ERAS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
CAI vs CRSP Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while CRSP trades at $50.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas CRSP's P/E ratio is -10.52. In terms of profitability, CAI's ROE is +0.16%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, CAI is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
CAI vs EWTX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while EWTX trades at $45.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas EWTX's P/E ratio is -24.37. In terms of profitability, CAI's ROE is +0.16%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, CAI is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for CAI.Check EWTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
CAI vs DNTH Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, DNTH has a market cap of 4.8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while DNTH trades at $86.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas DNTH's P/E ratio is -20.72. In terms of profitability, CAI's ROE is +0.16%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, CAI is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for CAI.Check DNTH's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
CAI vs TVTX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while TVTX trades at $49.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas TVTX's P/E ratio is -110.27. In terms of profitability, CAI's ROE is +0.16%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, CAI is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check TVTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
CAI vs FOLD Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CAI's ROE is +0.16%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, CAI is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for CAI.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
CAI vs AKRO Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CAI's ROE is +0.16%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, CAI is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for CAI.Check AKRO's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
CAI vs DFTX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, DFTX has a market cap of 4.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while DFTX trades at $33.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas DFTX's P/E ratio is N/A. In terms of profitability, CAI's ROE is +0.16%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, CAI is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check DFTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
CAI vs ADPT Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ADPT trades at $27.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ADPT's P/E ratio is -68.20. In terms of profitability, CAI's ROE is +0.16%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, CAI is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ADPT's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
CAI vs ALPN Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CAI's ROE is +0.16%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CAI is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ALPN's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
CAI vs LEGN Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, LEGN has a market cap of 4.3B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while LEGN trades at $23.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas LEGN's P/E ratio is -34.41. In terms of profitability, CAI's ROE is +0.16%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, CAI is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for CAI.Check LEGN's competition here
Opthea Limited (NASDAQ: OPT)
CAI vs OPT Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas OPT's P/E ratio is -1.52. In terms of profitability, CAI's ROE is +0.16%, compared to OPT's ROE of +1.18%. Regarding short-term risk, CAI is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for CAI.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
CAI vs PRTC Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas PRTC's P/E ratio is -3.78. In terms of profitability, CAI's ROE is +0.16%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, CAI is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for CAI.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
CAI vs MRTX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CAI's ROE is +0.16%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CAI is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check MRTX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
CAI vs RLAY Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while RLAY trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas RLAY's P/E ratio is -11.85. In terms of profitability, CAI's ROE is +0.16%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, CAI is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for CAI.Check RLAY's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
CAI vs CPRX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas CPRX's P/E ratio is 17.49. In terms of profitability, CAI's ROE is +0.16%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CAI is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
CAI vs ABCL Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ABCL trades at $11.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ABCL's P/E ratio is -22.01. In terms of profitability, CAI's ROE is +0.16%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, CAI is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ABCL's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
CAI vs XENE Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while XENE trades at $39.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas XENE's P/E ratio is -8.34. In terms of profitability, CAI's ROE is +0.16%, compared to XENE's ROE of -0.44%. Regarding short-term risk, CAI is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for CAI.Check XENE's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
CAI vs RYZB Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CAI's ROE is +0.16%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CAI is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for CAI.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
CAI vs CBAY Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CAI's ROE is +0.16%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CAI is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for CAI.Check CBAY's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
CAI vs AMLX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, AMLX has a market cap of 3.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while AMLX trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas AMLX's P/E ratio is -19.68. In terms of profitability, CAI's ROE is +0.16%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, CAI is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check AMLX's competition here
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
CAI vs ACAD Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ACAD trades at $21.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ACAD's P/E ratio is 9.56. In terms of profitability, CAI's ROE is +0.16%, compared to ACAD's ROE of +0.28%. Regarding short-term risk, CAI is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for CAI.Check ACAD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
CAI vs IOVA Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, IOVA has a market cap of 3.6B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while IOVA trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas IOVA's P/E ratio is -11.01. In terms of profitability, CAI's ROE is +0.16%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, CAI is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for CAI.Check IOVA's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
CAI vs ELVN Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while ELVN trades at $49.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas ELVN's P/E ratio is -29.63. In terms of profitability, CAI's ROE is +0.16%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, CAI is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for CAI.Check ELVN's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
CAI vs TNGX Comparison November 2026
Caris Life Sciences, Inc. (NASDAQ: CAI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CAI stands at 7.1B. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, CAI is priced at $25.23 on the NASDAQ, while TNGX trades at $21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CAI currently has a P/E ratio of 70.92, whereas TNGX's P/E ratio is -25.89. In terms of profitability, CAI's ROE is +0.16%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, CAI is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for CAI.Check TNGX's competition here